Health Trials

HER2-positive Gastroesophageal Junction Adenocarcinoma

2

Review clinical trials related to HER2-positive Gastroesophageal Junction Adenocarcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.

Participants needed: 257
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyUpdated: May 8, 2026Locations: 76Duration: 2 Years
Eligibility criteria

Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GE... [+4]

Patients who at time of data collection for this study are participating in or h... [+1]

Read more
Status: Recruiting

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

This trial is a single center, single arm, open label clinical study aimed at evaluating the efficacy and safety of the combination therapy of Disitamab Vedotin and trastuzumab in the treatment of advanced HER-2 positive gastric/gastroesophageal junction tumors

Participants needed: 35
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Cancer HospitalUpdated: Aug 27, 2024Locations: 1
Eligibility criteria

Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets ≥ 90 × 109/L, or [+3]

Known to be allergic to the received therapeutic drugs or excipients; [+16]

Read more